| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jane F Apperley | Q92881003 |
| European LeukemiaNet | Q114428076 | ||
| Alois Gratwohl | Q19859713 | ||
| Andreas Hochhaus | Q37829812 | ||
| Richard A. Larson | Q41899936 | ||
| Giuseppe Saglio | Q53342434 | ||
| François Guilhot | Q56362432 | ||
| Jorge Eduardo Cortes | Q60320900 | ||
| Hagop Kantarjian | Q60394812 | ||
| Michele Baccarani | Q66370907 | ||
| Frederick R. Appelbaum | Q75025725 | ||
| Dietger Niederwieser | Q88402151 | ||
| P2093 | author name string | Mary Horowitz | |
| Francisco Cervantes | |||
| Timothy Hughes | |||
| Bengt Simonsson | |||
| John Goldman | |||
| Rudiger Hehlmann | |||
| Michael Deininger | |||
| Richard Silver | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| chronic myeloid leukemia | Q729735 | ||
| P304 | page(s) | 1809-1820 | |
| P577 | publication date | 2006-05-18 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet | |
| P478 | volume | 108 |
| Q57805096 | Q57805096 |
| Q57805112 | Q57805112 |
| Q37610139 | A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours |
| Q42543085 | A case of leukemic retinopathy mimicking common ischemic retinopathies |
| Q45947009 | A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement. |
| Q37334945 | A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib |
| Q41877378 | A critical history of chromic myeloid leukemia |
| Q33597519 | A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib |
| Q49013184 | A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits. |
| Q34065271 | A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug |
| Q35800825 | A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat |
| Q46406540 | A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials |
| Q39259447 | A population-based study of chronic myeloid leukemia patients treated with imatinib in first line |
| Q49161617 | A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria. |
| Q38392676 | A review of the European LeukemiaNet recommendations for the management of CML. |
| Q39780753 | ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug |
| Q98154704 | Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients |
| Q37256808 | Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation |
| Q37870181 | Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients |
| Q89736492 | Additional chromosomal abnormalities in Philadelphia positive chronic myeloid leukemia |
| Q54453034 | Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort. |
| Q38856406 | Adiponectin enhances Imatinib anti-tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients |
| Q39591396 | Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register |
| Q37657488 | Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors |
| Q46742939 | Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis |
| Q39464336 | Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors |
| Q46413329 | Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007. |
| Q37027753 | Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias |
| Q39202778 | Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up. |
| Q38634736 | Allogeneic transplantation for CML in the TKI era: striking the right balance |
| Q36734508 | Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes |
| Q61776736 | Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia |
| Q47096076 | Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants |
| Q42979550 | Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. |
| Q97530383 | B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature |
| Q42930500 | BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia |
| Q54393349 | BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? |
| Q33781191 | BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia |
| Q41470558 | BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival |
| Q58459316 | BCR-ABL mutations in chronic myeloid leukemia–Not only detection |
| Q36026747 | BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase |
| Q54648205 | BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia. |
| Q84504522 | Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia |
| Q36884361 | Best Practices in Chronic Myeloid Leukemia Monitoring and Management |
| Q37845204 | Bilateral masculine mastoplasia associated with imatinib mesylate: a case report and literature review |
| Q53226422 | Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: a comparative study of 67 cases. |
| Q33747277 | Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. |
| Q33414487 | Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up |
| Q37027759 | Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure |
| Q33412495 | Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia |
| Q39065654 | CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease |
| Q37206193 | CML patients in the molecular era - report of five years experience of diagnosis and treatment in a single center |
| Q39969896 | Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience |
| Q37145279 | Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation |
| Q34890400 | Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? |
| Q37853793 | Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors |
| Q33580572 | Changing therapy from Glivecto a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports |
| Q35610886 | Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years. |
| Q46047569 | Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation |
| Q49721961 | Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. |
| Q27851450 | Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors |
| Q33844041 | Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy |
| Q35265868 | Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib |
| Q39516382 | Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? |
| Q37607094 | Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. |
| Q34617628 | Chronic myelogenous leukemia: treatment and monitoring |
| Q34657509 | Chronic myeloid leukaemia |
| Q95614708 | Chronic myeloid leukaemia |
| Q34620641 | Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q38018109 | Chronic myeloid leukemia (CML) in children: classical and newer therapeutic approaches |
| Q37365606 | Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective |
| Q46615390 | Chronic myeloid leukemia and HIV-infection |
| Q37356306 | Chronic myeloid leukemia in Asia |
| Q37467268 | Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India |
| Q37773845 | Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? |
| Q47203365 | Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience). |
| Q37369917 | Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. |
| Q57902808 | Chronic myeloid leukemia – some topical issues |
| Q34642865 | Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q37528598 | Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital |
| Q37163550 | Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet |
| Q33968037 | Chronic myeloid leukemia: mechanisms of blastic transformation |
| Q38028374 | Chronic myeloid leukemia: state of the art in 2012. |
| Q92914136 | Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type |
| Q46263937 | Chronic myeloproliferative diseases. Current therapeutic standards and new developments |
| Q37498272 | Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia |
| Q50793838 | Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. |
| Q35054717 | Clinical and biological predictors of outcome following relapse of CML post-allo-SCT |
| Q33926222 | Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia |
| Q57117892 | Clinical significance of dasatinib-induced pleural effusion in patients with de chronic myeloid leukemia |
| Q37994134 | Clinical trials in chronic myeloid leukemia |
| Q50546615 | Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical s |
| Q34521001 | Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia |
| Q43160325 | Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. |
| Q50852721 | Comparison of BCR/ABL1 mRNA levels by quantitative real-time PCR in peripheral blood and bone marrow specimens of patients with chronic myelogenous leukemia. |
| Q36374813 | Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders |
| Q45811588 | Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia |
| Q47739523 | Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation |
| Q38187388 | Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting |
| Q42117946 | Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy |
| Q42195178 | Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis |
| Q42976135 | Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application |
| Q54175557 | Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning? |
| Q34894883 | Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia |
| Q41673629 | Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia |
| Q46510723 | Current diagnostic requirements in chronic myeloid leukemia |
| Q42383073 | Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). |
| Q37847179 | Current status of agents active against the T315I chronic myeloid leukemia phenotype |
| Q37179388 | Current status of therapy for chronic myeloid leukemia: a review of drug development |
| Q46846313 | Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? |
| Q43281441 | Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose |
| Q92001805 | Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy |
| Q36694195 | Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. |
| Q39966752 | Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia |
| Q42650776 | Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options. |
| Q37714887 | Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. |
| Q37013074 | Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure |
| Q37523302 | Dasatinib in chronic myeloid leukemia: a review. |
| Q33384766 | Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial |
| Q33379225 | Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. |
| Q37692798 | Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). |
| Q33398716 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). |
| Q46050810 | Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance |
| Q33397085 | Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. |
| Q37815421 | Deactylase inhibition in myeloproliferative neoplasms |
| Q38199143 | Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia |
| Q44765944 | Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. |
| Q41501849 | Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. |
| Q37372801 | Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib |
| Q38006728 | Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia |
| Q40239073 | Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns |
| Q46179041 | Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform |
| Q37132863 | Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. |
| Q36857963 | Diagnostic problems in follow-up bone marrow biopsies of patients treated for acute and chronic leukaemias and MDS. |
| Q50848914 | Differences among young adults, adults and elderly chronic myeloid leukemia patients. |
| Q40864559 | Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial |
| Q54979821 | Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. |
| Q46004579 | Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. |
| Q36036294 | Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib |
| Q38899401 | Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? |
| Q54335282 | Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor? |
| Q54596369 | Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable? |
| Q40452878 | Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. |
| Q36263943 | Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. |
| Q37877650 | Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications |
| Q33388565 | Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group |
| Q44453492 | Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome |
| Q43607483 | Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). |
| Q42908265 | Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate |
| Q33632220 | Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia |
| Q34310190 | Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). |
| Q61808009 | Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia |
| Q53932853 | Effect of STAT3 inhibitor in chronic myeloid leukemia associated signaling pathway: a mathematical modeling, simulation and systems biology study. |
| Q46059109 | Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population |
| Q80559670 | Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha |
| Q26775622 | Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review |
| Q33886167 | Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia |
| Q35652450 | Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase |
| Q33536762 | Emerging drugs for chronic myeloid leukemia |
| Q36634266 | Emerging drugs in chronic myelogenous leukaemia |
| Q39120817 | Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide |
| Q37028628 | Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation |
| Q35664358 | Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale. |
| Q34046343 | Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy |
| Q90010384 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia |
| Q46419894 | European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. |
| Q26749324 | European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia |
| Q37026032 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. |
| Q90067699 | Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol |
| Q36804884 | Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. |
| Q46321468 | Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance |
| Q92506625 | Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase |
| Q50917057 | Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute. |
| Q34539293 | Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib |
| Q37973402 | Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia |
| Q37918304 | Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy |
| Q50548714 | Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. |
| Q90989428 | Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors |
| Q36533121 | Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib |
| Q43200905 | Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase |
| Q33844007 | Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast |
| Q42032199 | Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia |
| Q36769047 | Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells |
| Q37427140 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial |
| Q80388285 | First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts |
| Q42862831 | First annual report of the Austrian CML registry |
| Q59640163 | First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia |
| Q38066199 | First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation |
| Q38620872 | First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. |
| Q54540179 | First-line treatment with imatinib mesylate in patients with chronic phase chronic myeloid leukemia: experience of a public hospital in a developing country of South America. |
| Q39004368 | Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia |
| Q56967295 | Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial |
| Q35409569 | Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia |
| Q37306890 | Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study |
| Q28388806 | Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective |
| Q46606987 | Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia |
| Q42110946 | HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells |
| Q58023925 | Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories |
| Q37587749 | Harmonization of molecular monitoring of CML therapy in Europe |
| Q37657492 | Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors |
| Q79801204 | Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations |
| Q35900929 | High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. |
| Q33396265 | High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis |
| Q33886162 | High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. |
| Q37163734 | High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses |
| Q36366958 | High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial |
| Q37505017 | Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group |
| Q36846361 | How I monitor residual disease in chronic myeloid leukemia |
| Q35802202 | How I treat childhood CML. |
| Q37545067 | How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet |
| Q43117904 | Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case |
| Q30009113 | Identification of Dual Natural Inhibitors for Chronic Myeloid Leukemia by Virtual Screening, Molecular Dynamics Simulation and ADMET Analysis |
| Q37471688 | Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan |
| Q42316987 | Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome |
| Q46109621 | Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy |
| Q24186877 | Imatinib for treating newly diagnosed chronic myeloid leukemia patients |
| Q24241730 | Imatinib for treating patients with chronic myelogeneous leukemia |
| Q33844109 | Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy |
| Q38725366 | Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. |
| Q46735715 | Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. |
| Q79520876 | Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis |
| Q43078241 | Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. |
| Q36729603 | Imatinib: a review of its use in chronic myeloid leukaemia |
| Q43278551 | Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily |
| Q43475684 | Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia |
| Q40809808 | Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study |
| Q33518973 | Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia |
| Q36070796 | Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. |
| Q33886172 | Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. |
| Q40062210 | Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival |
| Q51916411 | Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. |
| Q34198055 | Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia |
| Q42409714 | Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance. |
| Q94507905 | In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' |
| Q35812209 | In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study |
| Q39410543 | Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib |
| Q42719442 | Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate |
| Q44129015 | Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia |
| Q36142412 | Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients. |
| Q41413446 | Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics |
| Q35779806 | Infectious disease screening among stem cell transplant donors: An Institutional experience in Saudi Arabia |
| Q50261890 | Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. |
| Q46174098 | Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results |
| Q43121013 | Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors |
| Q92182769 | Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response |
| Q40817501 | Initial treatment for patients with chronic myeloid leukemia |
| Q37315381 | Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. |
| Q38177354 | Insights on practice variations in the management of lymphoma and leukemia |
| Q37683539 | Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. |
| Q41294047 | Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System |
| Q33885583 | Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia. |
| Q45991055 | Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib. |
| Q41808582 | Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate |
| Q43200454 | Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. |
| Q36735557 | Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival |
| Q39700748 | LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells |
| Q54117334 | Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors. |
| Q37024667 | Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. |
| Q40302552 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia |
| Q33434675 | Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib |
| Q37461942 | Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors |
| Q46098047 | Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group |
| Q53196957 | Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. |
| Q54527295 | Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. |
| Q34293384 | Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations |
| Q44718887 | Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China |
| Q35073857 | Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib |
| Q35694453 | Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) |
| Q93062469 | Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia |
| Q93062406 | Long-term results of frontline dasatinib in chronic myeloid leukemia |
| Q49101349 | Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. |
| Q41952149 | Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy |
| Q44703351 | Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia |
| Q41210809 | MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. |
| Q35584176 | Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy |
| Q37004660 | Management of Bcr-Abl-positive leukemias with dasatinib |
| Q36997019 | Management of imatinib-resistant CML patients |
| Q36776423 | Management of imatinib-resistant patients with chronic myeloid leukemia |
| Q38101471 | Management options for refractory chronic myeloid leukemia: considerations for the elderly |
| Q51072279 | Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. |
| Q92206177 | Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP |
| Q81099047 | Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia |
| Q37896015 | Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia |
| Q37988569 | Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Q34016866 | Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia |
| Q37836923 | Mechanisms of resistance to BCR-ABL kinase inhibitors. |
| Q45029815 | Medical decision analysis for first-line therapy of chronic myeloid leukemia. |
| Q37202615 | Minimal residual disease diagnostics in myeloid malignancies in the post transplant period |
| Q38220970 | Minimal residual disease testing in hematologic malignancies and solid cancer |
| Q36237990 | Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia |
| Q46534692 | Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan. |
| Q37542270 | Molecular diagnosis of myeloproliferative neoplasms |
| Q35007333 | Molecular diagnostics in acute leukemias |
| Q53178315 | Molecular diagnostics in chronic myeloid leukemia. |
| Q37379320 | Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. |
| Q33750753 | Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission |
| Q38176284 | Molecular monitoring |
| Q53136807 | Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response. |
| Q37112773 | Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications |
| Q43082879 | Molecular monitoring in patients with chronic myelogenous leukemia |
| Q37738542 | Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value? |
| Q41768874 | Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis |
| Q41500344 | Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia |
| Q37696776 | Molecular techniques for the personalised management of patients with chronic myeloid leukaemia |
| Q37143280 | Monitoring molecular response in chronic myeloid leukemia |
| Q36153509 | Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response |
| Q42086556 | Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models. |
| Q36173719 | Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate |
| Q37044624 | Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors |
| Q43109564 | Mutations in ABL kinase domain are associated with inferior progression-free survival |
| Q34522789 | NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia |
| Q92461872 | Neuroprotective potential of imatinib in global ischemia-reperfusion-induced cerebral injury: possible role of Janus-activated kinase 2/signal transducer and activator of transcription 3 and connexin 43 |
| Q33383640 | New approved dasatinib regimen available for clinical use. |
| Q37810095 | New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia |
| Q45951595 | New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. |
| Q40996735 | Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients |
| Q47300241 | Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase |
| Q56962608 | Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia |
| Q33387519 | Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase |
| Q83978299 | Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd |
| Q40041737 | Nilotinib for the treatment of chronic myeloid leukemia |
| Q37586848 | Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance |
| Q39754589 | Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. |
| Q37295261 | Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy |
| Q37888714 | Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients |
| Q37117967 | Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia |
| Q45199223 | Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. |
| Q35596200 | Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure |
| Q36928803 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis |
| Q41007575 | PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase |
| Q90240742 | Pan-Cancer Analysis Reveals the Diverse Landscape of Novel Sense and Antisense Fusion Transcripts |
| Q37470939 | Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure |
| Q36988579 | Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia |
| Q37022464 | Part II: management of resistance to imatinib in chronic myeloid leukaemia |
| Q42843675 | Particular evolution of complex cytogenetic variants of chronic myeloid leukemia treated with imatinib |
| Q54607049 | Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. |
| Q36392598 | Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing |
| Q37464749 | Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia |
| Q46099532 | Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q33422320 | Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies |
| Q46976339 | Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia |
| Q92666581 | Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy |
| Q47877989 | Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series |
| Q38460343 | Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. |
| Q37132871 | Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia |
| Q58023854 | Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o |
| Q38139571 | Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia |
| Q33849146 | Practical management of patients with chronic myeloid leukemia |
| Q34417824 | Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations |
| Q37738567 | Predicting the response of CML patients to tyrosine kinase inhibitor therapy |
| Q37859303 | Predicting the response of CML patients to tyrosine kinase inhibitor therapy |
| Q46131305 | Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes |
| Q38095956 | Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring |
| Q54506990 | Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era. |
| Q46737739 | Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors |
| Q45895862 | Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia |
| Q51373837 | Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. |
| Q38028778 | Pushing the limits of targeted therapy in chronic myeloid leukaemia. |
| Q43206357 | Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio v |
| Q57818302 | Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors |
| Q37190370 | RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia. |
| Q61804715 | Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation |
| Q84329739 | Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors |
| Q38937497 | Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia |
| Q57021116 | Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia |
| Q35524714 | Recent advances in the path toward the cure for chronic myeloid leukemia |
| Q36089086 | Recommendations of the canadian consensus group on the management of chronic myeloid leukemia |
| Q51566996 | Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. |
| Q38557421 | Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine |
| Q37815384 | Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib |
| Q44679459 | Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. |
| Q37517596 | Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur |
| Q37517627 | Report of chronic myeloid leukemia in chronic phase from Cancer Institute (Women India Association), Chennai, 2002-2009. |
| Q41892288 | Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008. |
| Q43082874 | Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications |
| Q27028181 | Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options |
| Q46423528 | Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure |
| Q34293414 | Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations |
| Q33387517 | Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia |
| Q37060530 | Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy |
| Q53432205 | Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. |
| Q37810113 | Role of allogeneic transplantation in chronic myeloid leukemia |
| Q37810111 | Role of gene-expression profiling in chronic myeloid leukemia |
| Q34210528 | Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib |
| Q30891587 | Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. |
| Q43182892 | Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months |
| Q37510948 | Safety of conditioning agents for allogeneic haematopoietic transplantation |
| Q53329314 | Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice. |
| Q34622576 | Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia |
| Q48029208 | Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia |
| Q36852243 | Second-generation TKIs: which and when? |
| Q37811878 | Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia |
| Q28486093 | Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era |
| Q80786875 | Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain |
| Q41515301 | Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. |
| Q33561232 | Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response |
| Q35300745 | Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase |
| Q36725262 | Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia |
| Q46090252 | Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia |
| Q37662200 | Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. |
| Q37657478 | State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment |
| Q43011863 | Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. |
| Q37027402 | Strategies for overcoming imatinib resistance in chronic myeloid leukemia |
| Q27640723 | Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia |
| Q36331689 | Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar |
| Q54616756 | Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. |
| Q37148391 | Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? |
| Q36144079 | Suboptimal responses in chronic myeloid leukemia: implications and management strategies |
| Q37810110 | Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms |
| Q54616418 | Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. |
| Q46730765 | Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia |
| Q50896731 | Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. |
| Q35928884 | Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months. |
| Q37428659 | Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia |
| Q33903030 | Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia |
| Q37965564 | Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons |
| Q37038914 | Targeted therapy in chronic myeloid leukemia |
| Q33915973 | Targeted treatment of chronic myeloid leukemia: role of imatinib. |
| Q40217698 | The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib |
| Q37212678 | The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis |
| Q36967858 | The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias |
| Q38113416 | The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. |
| Q34451619 | The European LeukemiaNet: achievements and perspectives |
| Q37366701 | The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience |
| Q41842515 | The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. |
| Q35773205 | The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. |
| Q43254048 | The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy |
| Q33380383 | The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia |
| Q38134482 | The impact of molecular biology techniques on the management of newly diagnosed chronic myeloid leukemia patients in chronic phase. A review |
| Q55380318 | The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML). |
| Q89499597 | The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors |
| Q34032263 | The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase |
| Q89260367 | The third-time chronic myeloid leukemia in lymphoblastic crisis with ABL1 kinase mutation induced by decitabine, dexamethason combined with nilotinib and dasatinib |
| Q30754830 | The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad |
| Q39125275 | The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal |
| Q37635284 | The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up |
| Q37517632 | Therapeutic drug monitoring for imatinib: Current status and Indian experience |
| Q36822880 | Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). |
| Q36794538 | Therapeutic targets in chronic myeloid leukaemia |
| Q46616933 | Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study |
| Q58023832 | Therapy of Newly Diagnosed and Chronic-Phase Chronic Myeloid Leukemia |
| Q35944604 | Three-way complex variant translocation involving short arm chromosome (1;9;22)(p36;q34;q11) in a chronic myeloid leukemia patient |
| Q28551159 | Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics |
| Q39125281 | Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal |
| Q64925557 | Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population. |
| Q39446340 | Treatment and outcome of 2904 CML patients from the EUTOS population-based registry |
| Q53204377 | Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. |
| Q44774546 | Treatment of chronic phase chronic myeloid leukemia with imatinib |
| Q45871441 | Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry |
| Q33391185 | Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib |
| Q37062700 | Treatment options in imatinib-resistant chronic myelogenous leukemia |
| Q38181112 | Treatment recommendations for chronic myeloid leukemia |
| Q46010882 | Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. |
| Q35899653 | Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience |
| Q94592372 | Treatment-free remission in patients with chronic myeloid leukaemia |
| Q37098856 | Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry |
| Q37428676 | Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities |
| Q30242015 | Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? |
| Q37738539 | Tyrosine kinase inhibitors: the first decade |
| Q58752788 | Ultrasound assisted dispersive micro solid-phase extraction of four tyrosine kinase inhibitors from serum and cerebrospinal fluid by using magnetic nanoparticles coated with nickel-doped silica as an adsorbent |
| Q37889508 | Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners |
| Q37469835 | Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. |
| Q88046713 | [Choosing wisely recommendations in hematology and oncology] |
| Q83257633 | [Chronic myeloid leukemia. Diagnostics, therapy and future strategy] |
| Q53059587 | [Discovery of a novel spliceosome of ABL gene (ABL(Δexon7+35INS)) and its association with TKIs resistance in chronic myeloid leukemia]. |
| Q83735394 | [Hematopoietic stem cell transplantation. Indications, foundations and perspective] |
| Q88150038 | [How I treat newly diagnosed chronic myeloid leukemia in chronic phase] |
| Q35171271 | shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. |
Search more.